secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001753926-23-000657
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical Q1 net loss $6.3M; maintains IND filing timeline for NPM-119
---------------------------------------------------------------------------

- Cash $38.1M at March 31, 2023, down from $45.1M; sufficient to fund operations into H2 2024.
- R&D expense $4.0M (+48% YoY); operating expenses $6.6M (+69% YoY) driven by Second Sight acquisition costs.
- Net loss $6.3M vs $3.9M in Q1 2022; increase due to $2.7M higher operating expenses.
- Plans to file NPM-119 IND with FDA by mid-2023; if cleared, initiate LIBERATE-1 trial in Q3 2023 with top-line data in H1 2024.
- Expects to complete Cortigent IPO in Q3 2023; Vivani to retain control after offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/0001753926-23-000657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/g083544_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-000657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer